A new Mobilise-D scoping review: The clinical utility of digital mobility outcomes

Walking has the potential to be a rich indicator of health in many medical conditions. In recent years, scientific research has proposed more than 100 digital mobility outcomes (DMOs) that could be used to assess walking, and thereby monitor health status, using digital technologies. Though they show great promise, these DMOs require further validation.  Researchers must…

New publication: A roadmap to inform development, validation and approval of digital mobility outcomes: the Mobilise-D approach

Well known biomarkers such as blood pressure, respiration, temperature, pulse, and pain are frequently used by physicians and other health professionals to describe a patient’s health and disease status. In addition to these ‘signs of life’, there is another important aspect of people’s health and disease status, namely their mobility – how well they walk. Loss of physical mobility, such as reduced walking speed, is a significant feature of many health…

[Publication] Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes

Today’s smartwatches and activity bracelets, like FitBit, Apple, and Samsung, have motion sensors that can measure your daily activity. These technologies can tell you how much or little active you are, for example by counting your daily number of steps, heart rate or track your movements with GPS. In both basic and clinical research, similar…

New paper on gait tests in the hospital and at home in Parkinson’s Disease

The gait of patients with Parkinson’s Disease is typically assessed in a laboratory but with current developments in sensor technology, their gait could be assessed in the home environment as well. But how comparable are these two? Researchers from University Hospital Erlangen studied this question. In a reliability analysis, they compared standardized and supervised sensor-based…

Protocol paper for Mobilise-D scoping review published

Walking limitations are debilitating symptoms in many chronic diseases, and are highly related to quality of life, fall risk, and economic burden. Unsurprisingly, walking ability is a common target of pharmacological or behavioural intervention. Thanks to advances in wearable sensor technologies, it is now possible to objectively monitor how, and how much, patients walk in…

Walking in the lab and a real-world environment with Multiple Sclerosis

Our colleagues from Tel Aviv, the TASMC Mobilisers, studied the quality of walking of people with multiple sclerosis and healthy controls in two environments: a) a well-structured laboratory setting and b) during real-life, everyday walking using 24/7 monitoring.  During every-day walking, the patients took fewer steps, they walked more slowly, and the quality of their…

New publication on gait variability in Huntington’s disease

The expertise of our Mobilisers goes far beyond the Mobilise-D patient groups. Ultimately our findings should benefit anyone with mobility challenges, such as people suffering from Huntington’s Disease. Heiko Gaßner and colleagues explain more in their paper investigating gait variability as digital biomarkers of severity in Huntington’s disease. In this study, characteristic features of gait…